{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:53:53Z","timestamp":1780469633225,"version":"3.54.1"},"reference-count":59,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid antagonists block opioid receptors, a mechanism associated with utility in several therapeutic indications. Here, we review the sites of action, clinical uses, pharmacology, and general safety profiles of US Food and Drug Administration (FDA)-approved opioid antagonists. A review of the literature and product labels of opioid antagonists was conducted. The unique clinical uses of approved opioid antagonists are related to their ability to block opioid receptors centrally and\/or peripherally. Centrally acting opioid antagonists treat opioid and alcohol use disorders (AUDs) and reverse opioid overdose. Because the opioid system influences weight and metabolism, one opioid antagonist combination product is approved for chronic weight management; another, approved for adults with schizophrenia or bipolar I disorder, mitigates olanzapine-associated weight gain. Peripherally acting opioid antagonists are approved for opioid-induced constipation; another accelerates gastrointestinal recovery after bowel surgery. Opioid antagonists are generally well tolerated; they are not associated with physiologic dependence or abuse. However, opioid antagonists can precipitate acute opioid withdrawal in patients using or undergoing withdrawal from opioid agonists. Likewise, their use can confer a risk for opioid overdose if attempts are made to overcome opioid antagonist blockade of opioid receptors via the intake of additional opioids. Opioid receptor antagonists have diverse therapeutic benefits based on their respective pharmacology and sites of action; understanding their respective nuances facilitates the safe and effective use of these agents.<\/jats:p>","DOI":"10.1017\/s1092852924002189","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:08:19Z","timestamp":1732514899000},"page":"542-548","source":"Crossref","is-referenced-by-count":4,"title":["Opioid antagonists: clinical utility, pharmacology, safety, and tolerability"],"prefix":"10.1017","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marni E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-7816","authenticated-orcid":false,"given":"Mark S.","family":"Todtenkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Burgett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"S1092852924002189_r7","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S133"},{"key":"S1092852924002189_r54","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.018"},{"key":"S1092852924002189_r22","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119856850"},{"key":"S1092852924002189_r10","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2017-0028"},{"key":"S1092852924002189_r32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12163"},{"key":"S1092852924002189_r27","volume-title":"Revex [package insert]","year":"2006"},{"key":"S1092852924002189_r47","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S412357"},{"key":"S1092852924002189_r20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14674"},{"key":"S1092852924002189_r57","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.4.479"},{"key":"S1092852924002189_r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.10.134"},{"key":"S1092852924002189_r26","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.256115"},{"key":"S1092852924002189_r48","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.30"},{"key":"S1092852924002189_r52","volume-title":"Entereg [package insert]","year":"2022"},{"key":"S1092852924002189_r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.04.004"},{"key":"S1092852924002189_r58","volume-title":"Relistor [summary of product characteristics]","year":"2022"},{"key":"S1092852924002189_r43","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2017-0060"},{"key":"S1092852924002189_r8","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S313840"},{"key":"S1092852924002189_r4","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00203-2"},{"key":"S1092852924002189_r41","volume-title":"Narcan [package insert]","year":"2015"},{"key":"S1092852924002189_r50","volume-title":"Relistor [package insert]","year":"2020"},{"key":"S1092852924002189_r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.08.005"},{"key":"S1092852924002189_r35","volume-title":"Incorporating Alcohol Pharmacotherapies Into Medical Practice","year":"2009"},{"key":"S1092852924002189_r11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00632.2002"},{"key":"S1092852924002189_r5","volume-title":"Miller\u2019s Anesthesia","author":"Miller","year":"2009"},{"key":"S1092852924002189_r51","volume-title":"Symproic [package insert]","year":"2020"},{"key":"S1092852924002189_r18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18030280"},{"key":"S1092852924002189_r16","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714001305"},{"key":"S1092852924002189_r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.10.008"},{"key":"S1092852924002189_r2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00424-4"},{"key":"S1092852924002189_r24","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1343"},{"key":"S1092852924002189_r28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300811"},{"key":"S1092852924002189_r30","volume-title":"Opvee nasal spray [package insert]","year":"2023"},{"key":"S1092852924002189_r44","volume-title":"Suboxone [package insert]","year":"2023"},{"key":"S1092852924002189_r59","doi-asserted-by":"publisher","DOI":"10.5603\/PMPI.a2023.0025"},{"key":"S1092852924002189_r6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S221278"},{"key":"S1092852924002189_r39","volume-title":"Contrave [package insert]","year":"2020"},{"key":"S1092852924002189_r17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S1092852924002189_r23","doi-asserted-by":"publisher","DOI":"10.1210\/me.2008-0345"},{"key":"S1092852924002189_r12","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(86)90024-8"},{"key":"S1092852924002189_r49","volume-title":"Movantik [package insert]","year":"2014"},{"key":"S1092852924002189_r42","volume-title":"Zimhi [package insert]","year":"2021"},{"key":"S1092852924002189_r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2016.03.004"},{"key":"S1092852924002189_r55","unstructured":"55. European Medicines Agency. Moventig assessment report;2014. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/moventig-epar-public-assessment-report_en.pdf. Accessed April 25, 2023."},{"key":"S1092852924002189_r3","volume-title":"Basic and Clinical Pharmacology","author":"Katzung","year":"2012"},{"key":"S1092852924002189_r14","volume-title":"Lybalvi [package insert]","year":"2024"},{"key":"S1092852924002189_r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2015.01.016"},{"key":"S1092852924002189_r45","volume-title":"Zubsolv [package insert]","year":"2016"},{"key":"S1092852924002189_r19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.19121279"},{"key":"S1092852924002189_r1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852922000116"},{"key":"S1092852924002189_r53","volume-title":"Rizmoic [summary of product characteristics]","year":"2023"},{"key":"S1092852924002189_r38","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2011","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"S1092852924002189_r33","volume-title":"Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients, and Families","year":"2021"},{"key":"S1092852924002189_r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.02.032"},{"key":"S1092852924002189_r25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9479612.x"},{"key":"S1092852924002189_r31","unstructured":"31. US Food and Drug Administration. FDA approves prescription nasal spray to reverse opioid overdose [press release]; 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-prescription-nasal-spray-reverse-opioid-overdose. Accessed October 26, 2023."},{"key":"S1092852924002189_r36","volume-title":"Revia [package insert]","year":"2013"},{"key":"S1092852924002189_r37","volume-title":"Vivitrol [package insert]","year":"2022"},{"key":"S1092852924002189_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.02.033"},{"key":"S1092852924002189_r15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852924002189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:39:31Z","timestamp":1739972371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852924002189\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1092852924002189"],"URL":"https:\/\/doi.org\/10.1017\/s1092852924002189","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}